PMID- 22458771
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20120727
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 167
IP  - 2
DP  - 2012 Aug
TI  - Subacute cutaneous lupus erythematosus and its association with drugs: a 
      population-based matched case-control study of 234 patients in Sweden.
PG  - 296-305
LID - 10.1111/j.1365-2133.2012.10969.x [doi]
AB  - BACKGROUND: Numerous case reports about drug-induced (DI) subacute cutaneous 
      lupus erythematosus (SCLE) have been published. Various drug types with different 
      latencies has been proposed as triggers for this autoimmune skin disease. 
      OBJECTIVES: To evaluate the association between exposure to certain suspected 
      drugs (previously implicated to induce SCLE) and a subsequent diagnosis of SCLE. 
      METHODS: We performed a population-based matched case-control study in which all 
      incident cases of SCLE (n=34) from 2006 to 2009 were derived from the National 
      Patient Register. The control group was selected from the general population, 
      matched (1:10) for gender, age and county of residence. The data were linked to 
      the Prescribed Drug Register. Odds ratios (ORs) and 95% confidence intervals 
      (CIs) were calculated for the association between exposures to certain suspected 
      drugs and the development of SCLE. RESULTS: During the 6 months preceding SCLE 
      diagnosis, 166 (71%) of the patients with SCLE had at least one filled 
      prescription of the suspected drugs. The most increased ORs were found for 
      terbinafine (OR 52.9, 95% CI 6.6-infinity), tumour necrosis factor-alpha inhibitors (OR 8.0, 
      95% CI 1.6-37.2), antiepileptics (OR 3.4, 95% CI 1.9-5.8) and proton pump 
      inhibitors (OR 2.9, 95% CI 2.0-4.0). CONCLUSIONS: We found an association between 
      drug exposure and SCLE. More than one third of the SCLE cases could be attributed 
      to drug exposure. No significant OR was found for thiazides, which might be due 
      to longer latency and therefore missed with this study design. DI-SCLE is 
      reversible once the drug is discontinued, indicating the importance of screening 
      patients with SCLE for potentially triggering drugs. A causal relationship cannot 
      be established from this study and the underlying pathogenesis remains unclear.
CI  - (c) 2012 The Authors. BJD (c) 2012 British Association of Dermatologists.
FAU - Gronhagen, C M
AU  - Gronhagen CM
AD  - Division of Dermatology, Department of Clinical Sciences, Karolinska Institutet, 
      Danderyd Hospital, SE-182 88 Danderyd, Sweden. carina.gronhagen@ds.se
FAU - Fored, C M
AU  - Fored CM
FAU - Linder, M
AU  - Linder M
FAU - Granath, F
AU  - Granath F
FAU - Nyberg, F
AU  - Nyberg F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120705
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Prescription Drugs)
SB  - IM
CIN - Br J Dermatol. 2012 Aug;167(2):227-8. PMID: 22835019
MH  - Aged
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prescription Drugs/*adverse effects
MH  - Registries
MH  - Sweden/epidemiology
EDAT- 2012/03/31 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/03/31 06:00
PHST- 2012/03/31 06:00 [entrez]
PHST- 2012/03/31 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1111/j.1365-2133.2012.10969.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2012 Aug;167(2):296-305. doi: 10.1111/j.1365-2133.2012.10969.x. 
      Epub 2012 Jul 5.